GAO probe looks for FDA mishandling in heparin cases
This article was originally published in Scrip
US Representative Joe Barton, ranking member of the House Energy and Commerce Committee, has requested that the Government Accountability Officeconduct a thorough review of the US FDA's handling of the heparin saga. Committee investigators have discovered evidence suggesting gaps and discrepancies in the agency's assessment of deaths associated with Baxter International's heparin. Specifically, there are questions on whether the agency made an effort to use all of the tools that could have helped it establish a causal link, the November 19th letter stated.